Free tool
FAERS Monitor: Tryptyr
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 217370 or its brand name (Tryptyr, Acoltremon). Reports on generic versions are filed under their own applications.
Reports
6,335
Serious
166
3% of reports
Hospitalization
49
Death reported
22
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- eye irritation3,268
- drug ineffective1,382
- eye pain1,110
- dry eye604
- vision blurred511
- ocular hyperaemia489
- lacrimation increased280
- ocular discomfort260
- eye pruritus203
- condition aggravated190
- headache186
- visual impairment143
- eye swelling133
- inappropriate schedule of product administration102
- drug hypersensitivity98
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2024 | 1 |
| 2025 | 1,312 |
| 2026 | 5,022 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,047,824 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| eye irritationSignal | 3,268 | 199.8 | 194.8 | 611,195 |
| ocular discomfortSignal | 260 | 78.7 | 69.7 | 19,414 |
| eye painSignal | 1,110 | 66.6 | 63.1 | 70,447 |
| dry eyeSignal | 604 | 40.7 | 37.7 | 23,095 |
| ocular hyperaemiaSignal | 489 | 34.6 | 31.7 | 15,772 |
| lacrimation increasedSignal | 280 | 31.0 | 27.7 | 8,048 |
| eye pruritusSignal | 203 | 20.2 | 17.6 | 3,664 |
| vision blurredSignal | 511 | 12.4 | 11.4 | 5,358 |
| eye swellingSignal | 133 | 11.9 | 10.1 | 1,316 |
| visual impairmentSignal | 143 | 3.8 | 3.3 | 298 |
| drug ineffectiveSignal | 1,382 | 3.5 | 3.3 | 2,606 |
| condition aggravatedSignal | 190 | 2.1 | 1.8 | 106 |
| inappropriate schedule of product administration | 102 | 1.9 | 1.6 | 41 |
| drug hypersensitivity | 98 | 1.7 | 1.4 | 27 |
| headache | 186 | 1.0 | 0.9 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.